factor viia

Summary

Summary: Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation.

Top Publications

  1. pmc Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
    Blood 117:3199-208. 2011
  2. doi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
  3. doi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
  4. ncbi Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
  5. pmc Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium
    Samit Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    J Biol Chem 282:11849-57. 2007
  6. doi Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
    Aaron C Logan
    Stanford University School of Medicine, Stanford, CA, USA
    Ann Intern Med 154:516-22. 2011
  7. doi Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications
    Veronica Yank
    Stanford University, Stanford, CA, USA
    Ann Intern Med 154:529-40. 2011
  8. ncbi Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand
    Vijender R Vaidyula
    Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140, USA
    Diabetes 55:202-8. 2006
  9. ncbi Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Lancet 362:1953-8. 2003
  10. ncbi Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
    Todd A Hembrough
    EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
    Cancer Res 63:2997-3000. 2003

Research Grants

Detail Information

Publications242 found, 100 shown here

  1. pmc Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
    Prosenjit Sen
    Center for Biomedical Research, The University of Texas Health Science Center at Tyler, Tyler, TX, USA
    Blood 117:3199-208. 2011
    Recent studies have shown that factor VIIa (FVIIa) binds to the endothelial cell protein C receptor (EPCR), a cellular receptor for protein C and activated protein C, but the physiologic significance of this interaction is unclear...
  2. doi Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage
    Carl J Hauser
    Department of Surgery, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02216, USA
    J Trauma 69:489-500. 2010
    Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes.
  3. doi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
    ..A marked heterogeneity in the failure rate in all treatment groups was observed across participating centers. Adverse events, including overall thromboembolic events, were comparable between groups...
  4. ncbi Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
    ..No adverse effects of rFVIIa were observed. Although the number of patients is small, our study suggests that rFVIIa may be an alternative to platelet transfusions in patients with a severe congenital thrombocytopathy...
  5. pmc Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium
    Samit Ghosh
    Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    J Biol Chem 282:11849-57. 2007
    Although factor VII/factor VIIa (FVII/FVIIa) is known to interact with many non-vascular cells, activated monocytes, and endothelial cells via its binding to tissue factor (TF), the interaction of FVII/FVIIa with unperturbed endothelium ..
  6. doi Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
    Aaron C Logan
    Stanford University School of Medicine, Stanford, CA, USA
    Ann Intern Med 154:516-22. 2011
    Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who have hemophilia with inhibitors but has been applied to a wide range of off-label indications.
  7. doi Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications
    Veronica Yank
    Stanford University, Stanford, CA, USA
    Ann Intern Med 154:529-40. 2011
    Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.
  8. ncbi Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand
    Vijender R Vaidyula
    Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140, USA
    Diabetes 55:202-8. 2006
    ..2, factor VIII coagulant activity, and platelet CD40 ligand as well as decreases in factor VIIa, factor VII coagulant activities, and factor VII antigen...
  9. ncbi Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
    Thomas W Geisbert
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA
    Lancet 362:1953-8. 2003
    ..Here, we tested the notion that blockade of fVIIa/tissue factor is beneficial after infection with Ebola virus...
  10. ncbi Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism
    Todd A Hembrough
    EntreMed, Inc, Laboratory of Discovery Research, Rockville, Maryland 20850, USA
    Cancer Res 63:2997-3000. 2003
    ..coagulation on tumor growth, in vivo, we tested coagulation inhibitors specific for either tissue factor (TF)/factor VIIa (fVIIa) complexes or factor Xa (fXa) for antitumor activity...
  11. ncbi Safety profile of recombinant factor VIIa
    Harold R Roberts
    Division of Hematology, Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, USA
    Semin Hematol 41:101-8. 2004
    Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors...
  12. pmc The role of tissue factor and factor VIIa in hemostasis
    Nigel Mackman
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599 7035, USA
    Anesth Analg 108:1447-52. 2009
    ..However, the mechanism by which recombinant FVIIa restores hemostasis has not been clearly defined. In conclusion, the TF:FVIIa complex is essential for hemostasis and recombinant FVIIa is an effective hemostatic drug...
  13. doi Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest
    Roman M Sniecinski
    Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Cardiothorac Vasc Anesth 24:959-63. 2010
    ..This study was undertaken to determine what, if any, the impact of changing antifibrinolytic agents (from aprotinin to tranexamic acid) for deep hypothermic circulatory arrest cases would have on blood bank resource utilization...
  14. ncbi Factor viia for alveolar hemorrhage in microscopic polyangiitis
    Alan D Betensley
    Am J Respir Crit Care Med 166:1291-2. 2002
  15. ncbi Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity
    J López-Sagaseta
    Haematology Department and the Division of Cardiovascular Sciences, Laboratory of Thrombosis and Haemostasis, Clinica Universitaria School of Medicine, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
    J Thromb Haemost 5:1817-24. 2007
    ..Factor VII (FVII), the coagulation trigger upon tissue factor (TF) interaction, is a serine protease whose Gla domain is highly homologous to the Gla domain of protein C...
  16. ncbi The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry
    Peter Cameron
    Department of Epidemiology and Preventive Medicine, Monash University and Alfred Hospital Emergency and Trauma Centre, Melbourne, Australia
    Injury 38:1030-8. 2007
    ..The role of rFVIIa is not defined in this group of patients. Registries provide an opportunity to review the patients, reported response and adverse events for rFVIIa...
  17. doi Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism
    Zhengwen Ma
    Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, China
    Int J Gynecol Cancer 21:616-24. 2011
    ..However, it is not clear how tumor-associated macrophage and TF-FVIIa complex promotes EOC invasion. In the present study, we aimed to determine the mechanism by which interaction of TF-FVIIa and monocytes (MOs) promotes EOC metastasis...
  18. doi Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation
    Alexander Y Mitrophanov
    DoD Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, US Army Medical Research and Materiel Command, ATTN MCMR TT, 504 Scott Street, Ft Detrick, MD 21702, USA
    Thromb Res 128:381-90. 2011
    ..To elucidate the inherent ability of rFVIIa to modulate thrombin production, it is necessary to identify rFVIIa-induced effects that are compatible with the available biochemical knowledge about thrombin generation mechanisms...
  19. ncbi Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy
    Lennox Jeffers
    Center for Liver Disease, University of Miami School of Medicine, Miami, Florida 33125, USA
    Gastroenterology 123:118-26. 2002
    ....
  20. ncbi Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial
    Barton Sachs
    Texas Back Institute Clinical Research Organization, Plano, TX, USA
    Spine (Phila Pa 1976) 32:2285-93. 2007
    ..Randomized, placebo-controlled, double-blind, multicenter, Phase IIa study...
  21. pmc Structure of human factor VIIa and its implications for the triggering of blood coagulation
    A C Pike
    Structural Biology Laboratory, Chemistry Department, University of York, York YO10 5DD, United Kingdom
    Proc Natl Acad Sci U S A 96:8925-30. 1999
    b>Factor VIIa (EC 3.4.21.21) is a trypsin-like serine protease that plays a key role in the blood coagulation cascade. On injury, factor VIIa forms a complex with its allosteric regulator, tissue factor, and initiates blood clotting...
  22. ncbi Recombinant factor VIIa: its background, development and clinical use
    Ulla Hedner
    University of Lund, Sweden
    Curr Opin Hematol 14:225-9. 2007
    ..For the first time it was shown that pharmacological doses of FVIIa induced hemostasis...
  23. doi First 20 years with recombinant FVIIa (NovoSeven)
    U Hedner
    Department of Medicine, University of Lund, Lund, Sweden
    Haemophilia 17:e172-82. 2011
    ..By exploiting this mechanism of action, rFVIIa may also be effective in situations other than haemophilia, characterized by an impaired thrombin generation...
  24. ncbi Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation
    B Sørensen
    Center for Haemophilia and Thrombosis, Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark
    J Thromb Haemost 1:551-8. 2003
    ..Preliminary studies in patients substituted with recombinant factor VIIa demonstrated a marked change in the coagulation profile, in which the MaxVel and t,MaxVel shifted towards ..
  25. ncbi Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma
    Uri Martinowitz
    National Hemophilia Center, Tel Hashomer, Israel
    Can J Anaesth 49:S15-20. 2002
    ..It is approved for use in hemophilia patients, however, its use in trauma is still controversial due to the theoretical risk of thromboembolic complications...
  26. doi Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage
    Stephan A Mayer
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA
    N Engl J Med 358:2127-37. 2008
    ..We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes...
  27. ncbi The use of recombinant factor VIIa in the treatment of bleeding disorders
    Harold R Roberts
    Division of Hematology Oncology, Department of Medicine and The Carolina Cardiovascular Biology Center, 932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 7035, USA
    Blood 104:3858-64. 2004
    Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX...
  28. ncbi Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
    N S Key
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 91:4216-23. 1998
    ..Because TF is the principal cellular ligand for FVIIa, it is possible that increased binding to TF accounts for the diminished plasma FVIIa levels...
  29. pmc Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects
    Evert de Jonge
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Clin Diagn Lab Immunol 10:495-7. 2003
    ..we report that the activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of interleukin 6 (IL-6) and IL-8 in plasma...
  30. pmc Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006
    We conducted a post-hoc analysis on the effect of recombinant factor VIIa (rFVIIa) on coagulopathic patients from two randomized, placebo-controlled, double-blind trials of rFVIIa as an adjunctive therapy for bleeding in patients with ..
  31. ncbi Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa
    K Hicks
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 30:975-8. 2002
    ..The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B ..
  32. ncbi The use of recombinant factor VIIa in severe postpartum hemorrhage
    Shmuel Segal
    Barzilai Medical Center, Ashkelon, Israel
    Acta Obstet Gynecol Scand 83:771-2. 2004
  33. ncbi The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
    Maureane Hoffman
    Dis Mon 49:14-21. 2003
    ..We have previously proposed a platelet-dependent mechanism of action for high-dose factor VIIa (FVIIa; Novoseven, Novo Nordisk, Copenhagen, Denmark)...
  34. doi Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells
    G Demetz
    Deutsches Herzzentrum und 1 Medizinische Klinik, Technische Universitat Munchen, Lazarettstr 36, 80636 Munich, Germany
    Atherosclerosis 212:466-71. 2010
    Within atherosclerotic lesions Tissue Factor (TF)-Factor VIIa (FVIIa) not only contributes to thrombotic events but also alters vascular remodeling through enhancement of migration...
  35. ncbi Use of recombinant factor VIIa in inherited platelet disorders
    Mohamed Kaleelrahman
    Br J Haematol 125:95-6. 2004
  36. doi Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa
    Manijeh Lak
    Hematology Department, Hemophilia Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Clin Appl Thromb Hemost 16:294-300. 2010
    ..4%), 5 partial efficient treatment (14.7%) and two treatments inefficient (5.9%). Elimination therapy using steroid alone or with combination can terminate complete remission in most cases...
  37. ncbi Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII
    Walter H Dzik
    Blood Tranfusion Service, Massachusetts General Hospital, Boston, 02114, USA
    J Intensive Care Med 21:54-9. 2006
  38. ncbi Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII
    Stephan Malherbe
    Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
    Anesthesiology 100:443-5. 2004
  39. ncbi Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety
    M Von Depka
    Werlhof Institute for Haemostasis and Thrombosis, Karl Wiechert Allee, Hannover, Germany
    Haemophilia 11:18-23. 2005
    ..Recombinant FVIIa has demonstrated excellent efficacy and safety, even in patients refractory to other therapies...
  40. doi Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways
    Ying Wu
    Department of Internal Medicine, Affiliated Hospital of Jiangsu University, Jiangsu, PR China
    Cancer Invest 31:7-16. 2013
    ..The effects of FVIIa were TF-dependent and involving PAR2/MAPKs/NF-κB signal transduction pathways. Our study suggests that the links among PAR2/MAPKs/NF-κB may be blocked for effective treatments of colorectal cancers...
  41. ncbi Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIa
    M Gidiri
    Department of Obstetrics and Gynaecology, Hull and East Yorkshire Women and Children s Hospital, Hull, UK
    J Obstet Gynaecol 24:925-6. 2004
  42. doi Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial
    Raj K Narayan
    Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio, USA
    Neurosurgery 62:776-86; discussion 786-8. 2008
    ..Recombinant factor VIIa (rFVIIa) is a hemostatic agent that has been shown to limit hemorrhage expansion and which, therefore, could ..
  43. ncbi A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome
    Benjamin W Dart
    Department of Surgery, Division of Surgical Critical Care, University of Tennessee College of Medicine, Chattanooga Unit, Chattanooga, Tennessee 37403, USA
    J Trauma 57:171-4. 2004
  44. doi Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting
    Aaron C Logan
    Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Hematology Am Soc Hematol Educ Program 2010:153-9. 2010
    Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in the setting of hemorrhage associated with factor VIII or factor IX inhibitors in patients with congenital or acquired hemophilia...
  45. pmc Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients
    Bartolomeu Nascimento
    Tory Regional Trauma Centre, Sunnybrook Health Sciences Centre, University of Toronto, Canada
    Clinics (Sao Paulo) 66:101-6. 2011
    To determine whether recombinant factor VIIa (rFVIIa) is associated with increased survival and/or thromboembolic complications.
  46. ncbi Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion
    Leonie J Siegel
    Department of Anesthesiology, Mannheim University Clinic, Germany
    Anesthesiology 100:441-3. 2004
  47. doi Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports
    Barbara L Leighton
    Washington University in Saint Louis School of Medicine, St Louis, Missouri 63110, USA
    Anesthesiology 115:1201-8. 2011
    ..Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue ..
  48. doi Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment
    Gilead Shafir
    Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel
    J Biomed Mater Res A 91:1056-64. 2009
    ..The activated double bonds were then used for covalent binding, via Michael addition reaction, of recombinant factor VIIa and human serum albumin to the surface of these nanoparticles...
  49. ncbi Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties
    L Fan
    Center de Recherche, Hopital Sainte Justine, Université de Montréal Montréal, Quebec, Canada
    J Thromb Haemost 3:1056-63. 2005
    ..We speculate that FVIIa-TF-PAR-2 inhibitors may be effective in suppressing cell proliferation...
  50. ncbi Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures
    R D'Oiron
    The Haemophilia Center, Hopital Bicetre, Paris Sud, France
    Thromb Haemost 83:644-7. 2000
    ..In an attempt to find an alternative treatment regimen, we used recombinant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk, Denmark) as first-line therapy in 3 patients with Glanzmann's thrombasthenia ..
  51. ncbi Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa
    Stephen M Pastores
    Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue M 210, New York, NY 10021, USA
    Chest 124:2400-3. 2003
    ..Recombinant factor VIIa (rFVIIa) is an approved agent for the treatment of bleeding in patients with hemophilia A or B and the presence ..
  52. doi Successful treatment of severe retro-peritoneal bleeding with recombinant factor VIIa in women with placenta percreta invading into the left broad ligament: unusual repeated ante-partum intra-abdominal bleeding
    Muhieddine Seoud
    Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
    J Obstet Gynaecol Res 36:183-6. 2010
    ..bleedings in a woman with placenta percreta invading into the left broad ligament, in whom recombinant factor VIIa was effective for controlling severe retro-peritoneal bleeding...
  53. doi Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study
    J Spira
    Omri Laboratories Ltd, Nes Ziona, Israel
    Haemophilia 16:910-8. 2010
    Recombinant activated factor VIIa (FVIIa) is a bypassing agent used to treat bleeding episodes in haemophilia patients with inhibitors to factor VIII (FVIII) and factor IX...
  54. pmc Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications
    Ramesh C Nayak
    Center for Biomedical Research, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA
    Blood 114:1974-86. 2009
    ..A small fraction of EPCR is also localized intracellularly in the recycling compartment. Factor VIIa (FVIIa) or activated protein C binding to EPCR promoted the internalization of EPCR...
  55. ncbi Potent 4-amino-5-azaindole factor VIIa inhibitors
    Huiyong Hu
    Celera Genomics, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:4567-70. 2006
    ..The 4-amino-5-azaindole as an amidino-benzimidazole replacement is described. A series of potent and selective analogs were discovered and showed desirable ex vivo efficacy as measured by PT...
  56. pmc Molecular dynamics simulations and functional characterization of the interactions of the PAR2 ectodomain with factor VIIa
    Qing Zhang
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Proteins 77:559-69. 2009
    ....
  57. ncbi Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial
    Stephan A Mayer
    Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Neurocrit Care 4:206-14. 2006
    ..We conducted this trial to evaluate the safety of activated recombinant factor VII (rFVIIa; NovoSeven) for preventing early hematoma growth in acute ICH...
  58. ncbi On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation
    Grigoris T Gerotziafas
    Department of Haematology, Theagenion Cancer Hospital, 2 A Simeonidi Street, 54161 Thessaloniki, Greece
    Br J Haematol 117:705-8. 2002
    ..These data indicate that rFVIIa accelerated thrombin generation without significant increase of generated thrombin...
  59. ncbi Oxidation of methionine residues in coagulation factor VIIa
    T Kornfelt
    Novo Nordisk A S, Niels Steensens Vej 1, Gentofte, Denmark
    Arch Biochem Biophys 363:43-54. 1999
    ..However, native and oxidized FVIIa appeared to bind lipidated TF with indistinguishable affinities...
  60. ncbi Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa
    R M Sugg
    Department of Neurology, The University of Houston Medical School, Houston, TX 77030, USA
    Neurology 67:1053-5. 2006
    We report myocardial injury in 20 recombinant factor VIIa (rFVIIa) treated and 110 nontreated patients with intracerebral hemorrhage. Patients were treated or received standard medical management...
  61. ncbi Determinants of futility of administration of recombinant factor VIIa in trauma
    Deborah M Stein
    R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Trauma 59:609-15. 2005
    Off-label" use of human coagulation factor VIIa (FVIIa) is presently restricted to patients in extremis at our institution...
  62. ncbi Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein
    Guenther Boden
    Division of Endocrinology, Diabetes, and Metabolism and the Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Am J Physiol Endocrinol Metab 292:E1333-9. 2007
    ..Circulating TF procoagulant activity (TF-PCA), factor VIIa activity (FVIIa; clotting assays), TF antigen (TF-Ag; ELISA), prothrombin fragment 1.2 (F1...
  63. ncbi Factor VIIa replacement therapy in factor VII deficiency
    K Brummel Ziedins
    Department of Biochemistry, University of Vermont, Burlington, Vermont 05405, USA
    J Thromb Haemost 2:1735-44. 2004
    ..3-0.7 nmol L(-1)/equivalent dose: 0.8-1.8 micro g kg(-1)) is approximately 1/10 that currently used in treating FVII-deficient individuals and suggests that therapies should be altered relative to the concentration of the FVII zymogen...
  64. doi Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)
    L A Valentino
    Rush University Medical Center, Chicago, IL 60612 3833, USA
    Haemophilia 18:554-60. 2012
    ..Frequently bleeding CHwI patients (≥ 4 episodes in 3 months) prescribed recombinant factor VIIa (rFVIIa) as first-line therapy, or their caregivers, completed daily diaries for 3-6 months capturing bleeding ..
  65. doi Recombinant factor VIIa for warfarin-associated intracranial bleeding
    Can Ilyas
    Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Clin Anesth 20:276-9. 2008
    To examine the efficacy of recombinant factor VIIa (rVIIa) in reversing warfarin-induced coagulopathy in trauma patients presenting with intracranial hemorrhage (ICH).
  66. ncbi Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective
    Michael Kalina
    Christiana Care Hospital in Newark, Del, USA
    Del Med J 83:109-13. 2011
    ..Massive transfusion in obstetric patients is rare. Recombinant Factor VIIa (rFVIIa) use in trauma patients with massive transfusion is efficacious...
  67. ncbi Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa
    Asim Javed
    Combined Military Hospital, Rawalpindi, Pakistan
    J Ayub Med Coll Abbottabad 21:171-3. 2009
    ....
  68. doi Extensive small-angle X-ray scattering studies of blood coagulation factor VIIa reveal interdomain flexibility
    Charlotte Rode Mosbaek
    Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK 2100 Copenhagen, Denmark
    Biochemistry 49:9739-45. 2010
    Blood coagulation factor VIIa (FVIIa) is used in the treatment of replacement therapy resistant hemophilia patients, and FVIIa is normally activated upon complex formation with tissue factor (TF), potentially in context with structural ..
  69. ncbi Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)
    S Segal
    Department of Obstetrics and Gynecology, Ben Gurion University of the Negev, Barzilai Medical Center, Ashkelon, Israel 78306
    Arch Gynecol Obstet 268:266-7. 2003
    ..Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage...
  70. ncbi Recombinant factor VIIa. An update on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Thromb Haemost 93:1027-35. 2005
    ..Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications...
  71. doi Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer
    Philippe Zerbib
    Inserm ERI 9, Faculté de Médecine Lille, France Université de Lille 2, EA2693, Lille, France
    J Surg Res 153:239-45. 2009
    ..colorectal cancer (CRC) cells is involved in tumoral angiogenesis and metastasis progression, after binding of factor VIIa (FVIIa) to TF and generation of TF-FVIIa activity...
  72. doi A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia
    Z H Yuan
    Department of Emergency, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China
    J Clin Neurosci 17:685-93. 2010
    ..In conclusion, the use of rFVIIa reduces the growth of the hematoma but does not improve patient survival or functional outcome after ICH; in addition, rFVIIa increases the incidence of arterial TAE...
  73. doi Use of recombinant factor VIIA for control of combat-related haemorrhage
    Susan I Woodruff
    San Diego State University, School of Social Work, San Diego, USA
    Emerg Med J 27:121-4. 2010
    ..Recombinant activated human coagulation factor VII (rFVIIa), an intravascular strategy to promote clotting, is being used as an adjunct to surgical control of bleeding in combat trauma patients...
  74. doi Use of clotting factors and other prohemostatic drugs for obstetric hemorrhage
    Frederic J Mercier
    Departement d Anesthesie Reanimation, Hopital Antoine Beclere, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique Hopitaux de Paris, Universite Paris XI, Clamart, France
    Curr Opin Anaesthesiol 23:310-6. 2010
    ..To guide the optimal use of blood products and to clarify the indications for prohemostatic drugs in obstetric hemorrhage...
  75. doi Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand
    Oliver Flower
    Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
    Blood Coagul Fibrinolysis 21:207-15. 2010
    Recombinant factor VIIa (rFVIIa) is used in the treatment of life-threatening haemorrhage that is refractory to conventional treatment. The evidence supporting this practice in patients with liver disease is very limited...
  76. ncbi Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa
    Andrew Dao
    Department of Internal Medicine, California Pacific Medical Center, San Francisco, Calif, USA
    Am J Med 118:1172-3. 2005
  77. ncbi Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients
    Ampaiwan Chuansumrit
    Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
    Blood Coagul Fibrinolysis 21:354-62. 2010
    ..These results support the safety and potential benefit of rFVIIa for control and prevention of hemorrhage in pediatric patients without congenital hemophilia...
  78. doi Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system
    Maisha T Robinson
    Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA
    Stroke 41:1459-63. 2010
    Recombinant Factor VIIa decreases hematoma growth after spontaneous intracerebral hemorrhage (ICH) and rapidly decreases international normalized ratios in patients on warfarin but is also associated with an increased risk for ..
  79. ncbi Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits
    L Chi
    Pfizer Global R and D, Ann Arbor Laboratories, Cardiovascular Pharmacology, Ann Arbor, MI 48105, USA
    J Thromb Haemost 2:85-92. 2004
    ..This model may be useful for evaluating in vivo efficacy of new antithrombotic drugs, particularly TF-FVIIa inhibitors...
  80. doi Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin
    Pancras C Wong
    Thrombosis Research, Bristol Myers Squibb Company, Pennington, New Jersey, USA
    Thromb Haemost 104:302-10. 2010
    ..Under these experimental conditions, a FXIa inhibitor did not prevent TF-induced platelet aggregation...
  81. ncbi Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors
    Katrin Groebke Zbinden
    F Hoffmann La Roche Ltd, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 15:817-22. 2005
    Proof of concept experiments have shown that tissue factor/factor VIIa inhibitors have antithrombotic activity without enhancing bleeding propensity...
  82. ncbi Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor
    P Laguna
    Department of Paediatrics, Haematology, and Oncology, Warsaw Medical University, Poland
    Haemophilia 11:2-4. 2005
    ..Duration in the therapy and intervals between rFVIIa doses depended on the severity of bleeding. rFVIIa was proven to be highly effective and no side-effects of the product were observed...
  83. ncbi A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo
    Alan G Olivero
    Department of Medicinal Chemistry, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:9160-9. 2005
    The serine protease factor VIIa (FVIIa) in complex with its cellular cofactor tissue factor (TF) initiates the blood coagulation reactions. TF...
  84. doi Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association
    M Margaret Knudson
    Department of Surgery, University of California, San Francisco, USA
    J Am Coll Surg 212:87-95. 2011
    ..We hypothesized that we could describe the setting in which rFVIIa would be most successful in arresting hemorrhage after injury...
  85. pmc Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor
    Y Z Ohkubo
    Beckman Institute for Advanced Science and Technology, University of Illinois, Urbana, IL, USA
    J Thromb Haemost 8:1044-53. 2010
    The molecular mechanism of enhancement of the enzymatic activity of factor VIIa by tissue factor (TF) is not fully understood, primarily because of the lack of atomic models for the membrane-bound form of the TF-FVIIa complex.
  86. pmc Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
    Alicia M Mohr
    Department of Surgery, New Jersey Medical School, Newark, New Jersey, USA
    Crit Care 9:S37-42. 2005
    ..Further prospective, randomized, and placebo-controlled clinical trials will yield more information on the role of rFVIIa in the management of traumatic bleeding...
  87. ncbi Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    B Siegmund
    Haemophilia 11:638-41. 2005
  88. doi A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome
    Jean Louis Vincent
    Department of Intensive Care, Hopital Erasme, Universite Libre de Bruxelles, Belgium
    Crit Care Med 37:1874-80. 2009
    To evaluate the safety and efficacy of active site inactivated recombinant factor VIIa (FFR-rFVIIa) in patients with acute respiratory distress syndrome.
  89. doi The role of recombinant-activated factor VII in bleeding trauma patients
    Richard P Dutton
    Department of Anesthesiology, University of Maryland School of Medicine, Division of Anesthesiology, R Adams Cowley Shock Trauma Center, University of Maryland Medical System, Baltimore, Maryland 21201, USA
    Curr Opin Anaesthesiol 22:299-304. 2009
    ..Exsanguinating hemorrhage and postshock organ failure account for 35-40% of deaths from trauma, and there is an increasing recognition of the importance of coagulopathy in the evolution of this disease...
  90. ncbi Recombinant-activated coagulation factor VIIa (NovoSeven): current development
    R B Weiskopf
    Novo Nordisk A S, Novo Alle, DK 2880 Bagsvaerd, Denmark
    Vox Sang 92:281-8. 2007
    ..This review summarizes the current development of rFVIIa, focusing on results of prospective, randomized clinical trials...
  91. doi Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors
    Chris Knight
    RTI Health Solutions, Williams House, Manchester, M15 6SE, UK
    Adv Ther 26:68-88. 2009
    ..Our aim is to establish robust estimates of the efficacy, speed of bleed resolution, and adverse event profile of both rFVIIa and aPCC...
  92. pmc Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome
    Patricia Redecha
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:3453-61. 2008
    ..An antibody specific for human TF that has little impact on coagulation, but potently inhibits TF/Factor VIIa (FVIIa) signaling through PAR2, inhibited aPL-induced neutrophil activation in mice that expressed human TF...
  93. ncbi In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature
    Hanne Nedergaard
    Pharmaceutics, BIOPHARM, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Ther 30:1309-15. 2008
    ..The first-generation rFVIIa formulation is stable when stored under refrigeration. A new formulation has been developed for storage at room temperature, which may improve patients' access to treatment during bleeding episodes...
  94. ncbi Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa
    Mamoru Shoji
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Drug Target 16:185-97. 2008
    ..As a transmembrane receptor for coagulation factor VIIa (fVIIa), TF forms a high-affinity complex with its cognate ligand, which is subsequently internalized through ..
  95. doi The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface
    Cees Weeterings
    Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 112:3227-33. 2008
    Several lines of evidence suggest that recombinant factor VIIa (rFVIIa) is able to activate factor X on an activated platelet, in a tissue factor-independent manner...
  96. doi The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial?
    Nathaniel McQuay
    Department of Surgery, University of Pennsylvania Health System, Trauma Critica Division, St Luke s Hosptial, USA
    J Neurosurg 111:666-71. 2009
    ..This study evaluates the outcomes of using rFVIIa as first-line therapy in patients with a severe TBI requiring emergent craniotomy that are coagulopathic...
  97. doi Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
    P Salaj
    Institute of Hematology and Blood Transfusion, Prague, Czech Republic
    Haemophilia 15:752-9. 2009
    ..This registry has provided a unique insight into the bleeding patterns of inhibitor patients, highlighting the importance of early treatment initiation and appropriate starting dose...
  98. doi Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage
    A Shaun Rowe
    Department of Pharmacy, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA
    Am J Health Syst Pharm 67:361-5. 2010
    The use of coagulation factor VIIa (recombinant) for the treatment of warfarin-induced intracranial hemorrhage (ICH) is described.
  99. doi Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients
    Carlos V R Brown
    Department of Surgery, University of Texas Southwestern Medical School Austin, University Medical Center Brackenridge Trauma Services, Austin, Texas 78701, USA
    J Trauma 68:348-52. 2010
    ..We hypothesize that rFVIIa would provide an effective and cost efficient means of correcting coagulopathy in patients with traumatic brain injury undergoing emergent craniotomy...
  100. ncbi Recombinant factor VIIa in major abdominal surgery and liver transplantation
    J da Silva Viana
    Faculty of Medicine, University of Coimbra, Coimbra, Portugal
    Transplant Proc 38:818-9. 2006
    ..The majority of the reviewed investigators accepted the use of rFVIIa after or simultaneously with the use of aprotinin; no data refute the safety of this association...
  101. doi Current status on tissue factor activation of factor VIIa
    Egon Persson
    Haemostasis Biochemistry, Novo Nordisk A S, Måløv, Denmark
    Thromb Res 125:S11-2. 2010
    Free factor VIIa displays a zymogen-like behavior with low intrinsic activity...

Research Grants70

  1. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    ..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
  2. Lipid Regulation of Thrombin Generation
    Barry R Lentz; Fiscal Year: 2010
    ..role in other key proteolytic reactions involved in blood coagulation? Factor IXa with its cofactor VIIIa and factor VIIa with its cofactor tissue factor activate factor X to Xa...
  3. Tissue Factor Pathway Inhibitor Binding Proteins on Endo
    ALAN MAST; Fiscal Year: 2005
    Tissue factor pathway inhibitor (TFPI) rapidly inhibits both factor Xa and the factor VIIa/tissue factor catalytic complex. Thus, it is thought to be the most important inhibitor of the initiation of blood coagulation...
  4. BIOCHEMISTRY OF VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1990
    ..We will study the kinetics of activation of Gla-domainless factor IX by factor XIa/calcium and by factor VIIa/tissue factor/calcium...
  5. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 2001
    ..We will also examine a hypothesis that factor VIIa binds to tissue factor (TF) with a significantly higher affinity than factor VII and that the EGF2 domain of ..
  6. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    ..autoantibodies and autoantibodies to tissue factor pathway inhibitor (TFPI), a critical inhibitor of both factor VIIa/TF and factor Xa...
  7. FACTOR XI PHYSIOLOGY AND MOLECULAR BIOLOGY
    David Gailani; Fiscal Year: 2000
    ..In current models of hemostasis, normal coagulation is initiated by the factor VIIa/tissue factor complex, and not through contact activation...
  8. BIOCHEMISTRY OF NORMAL & ABNORMAL VARIANTS OF FACTOR IX
    S Bajaj; Fiscal Year: 1993
    ..Tissue factor pathway inhibitor (TFPI) consists of three kunitz-type domains. The first domain binds to factor VIIa and the second domain binds to factor Xa. The function of the third domain is as yet not clear...
  9. Studies of rHuTPO in ITP and of rVlla in Liver Disease
    David Kuter; Fiscal Year: 2006
    ..undergoing an invasive hepatobiliary procedure is reduced by pre-procedure treatment with FFP or recombinant factor VIIa (rVIIa)...
  10. Deoxyribozymes for Bioorganic Chemistry
    Scott K Silverman; Fiscal Year: 2010
    ..further degradation, and (b) as an approach for in vivo zymogen activation, such as formation of coagulation factor VIIa as a novel approach to treatment of bleeding...
  11. Induction of Tissue Factor by Patient Sera in HUS
    Eric Grabowski; Fiscal Year: 2007
    ..an antibody directed against activated factor X, recombinant-activated protein C, and active site-inhibited r-factor VIIa. A confirmation that shiga toxin and cytokines present in patient sera augment the TF pathway in our model ..
  12. Biochemistry of Normal & Abnormal Variants of Factors IX
    S Bajaj; Fiscal Year: 2006
    This application is based upon the conviction that activation of factor IX (FIX) by the tissue factor/factor VIIa (TF/VIIa) complex represents a key step in the initiation of coagulation by the extrinsic pathway...
  13. BLOOD COAGULATION HOMESTASIS: REGULATION OF TFPI
    Alan Schwartz; Fiscal Year: 2003
    ..inhibitor of coagulation is tissue factor pathway inhibitor (TFPI), which produces feedback inhibition of the factor VIIa/tissue factor complex and directly binds and inhibits factor Xa...
  14. Fluorogenic Assays for Factor Vlla and Tissue Factor
    RICHARD JENNY; Fiscal Year: 2006
    b>Factor VIIa and tissue factor (TF) are essential proteins for the initiation of blood coagulation. Blood coagulation is initiated when cryptic TF becomes exposed on the surface of vascular cells where it can bind circulating factor VIla...
  15. FACTOR X ACTIVATION BY THE EXTRINSIC PATHWAY
    Sriram Krishnaswamy; Fiscal Year: 2000
    ..The enzyme complex (extrinsic Xase) that catalyses this reaction is composed of the serine protease, factor VIIa, and the integral membrane protein, tissue factor, that associate tightly on a cellular or phospholipid surface ..
  16. Association of tissue factor pathway inhibitor with endothelium
    ALAN MAST; Fiscal Year: 2009
    ..Inhibitor (TFPI) is an endothelial- associated anticoagulant protein that directly inhibits the Tissue Factor-factor VIIa (TF-fVIIa) catalytic complex preventing intravascular thrombosis, disseminated intravascular coagulation, tumor ..